Management

Alexander Ivashchenko, Prof., DSc.
Chief Scientific Officer, Founder of ChemRar Group of Companies

Dr. Ivashchenko holds Doctor of Sciences (1982) and Professor (1988) degrees. He is the Distinguished Inventor of the Russian Federation (1984), the winner of the State Prize of the USSR (1983) and the Prize of the Council of Ministers of the USSR (1989).Dr. Ivashchenko is a world-recognized expert in the field of medicinal chemistry. He has been instrumental in advancing and supervising a series of studies on the development of innovative drugs for the treatment of cancer, hepatitis C, influenza, Alzheimer’s disease, schizophrenia and obesity. Many of these studies are currently at the clinical stage. Dr. Ivashchenko is a co-author of over 750 scientific publications and patents. Alex V. Ivashchenko (born March 24, 1945) is a founder and CSO of Chemical Diversity Research Institute (CDRI) of the Center of High Technologies “ChemRar” (Khimki, Moscow region), ChemDiv Inc. (USA), AllaChem LLC (USA), Avineuro Pharmaceuticals (USA).

Andrey Ivashchenko, Prof., DSc.
Chairman of the Board, ChemRar Group of Companies, Professor of the Russian Academy of Sciences

Entering the small molecule business in 1995, Dr. Ivashchenko has turned it into the advanced privately owned Drug Discovery and Development center in Russia. ChemRar group has seed-financed or spin-out a number of biotech companies involved in medicine’s research from basic science discovery to the development of new drugs in Oncology, CNS, Virology, incl. HIV, drug formulation and production. He also was a government advisor to the Pharma 2020 program and one of Key Opinion Leaders on industrial policy of Russia’s Pharma Industry. Dr. Ivashchenko is a co-founder and one of initiators of creation of the Biopharmaceutical cluster «Northern» based on MIPT, Fund of development of Phystech-lyceum and phystech-schools, conducts active public, scientific and implementation work within strategy «PHYSTECH XXI» for development of a modern technopolis round MIPT.

Andrey Ivashchenko is a member of various public and government organizations, such as Advisory Council at the Government of the Russian Federation, Advisory Council at Ministry of Industry and Trade of RF on development of pharmaceutical industry, the Subcommittee at the Government commission for protection of public health, a member of the Supervisory Board of the Fund for Assistance to Small Innovative Enterprises in the scientific and technical area of “Skolkovo” fund, the member of Advisory council on development of biotechnologies, pharmaceutical and the medical industry at the Russian State Duma Committee on Industry etc.

In 2015 Andrey Ivashchenko headed NeuroNet «Market» group of designing and assembling of NeuroNet roadmap of the National Technological Initiative (NTI). Professor Ivashchenko has authored and coauthored more than 50 certificates and patents, over 150 scientific publications in Russia and abroad, more than 1000 international deals (USA, Europe, Japan).

Nikolay Savchuk, Ph.D.
Chairman of the Board of the Chemical Diversity Research Institute, Member of the Board of ChemRar Group of Companies

Prior to joining ChemRar, Dr. Savchuk held various business and research management positions in the IT industry with companies in Singapore and Russia. Since joining the company he has held positions of increasing responsibility including Director of Information Technologies, and Director and Vice President of Business Development. Dr. Savchuk has a PhD in Physics and Mathematics from Moscow Institute of Physics and Technology. He is the author of over 60 scientific papers.

Dmitry Kravchenko, DSc.
General Director of Chemical Diversity Research Institute, Member of the Board of ChemRar Group of Companies

Dmitry Kravchenko has more than 25 years of experience in the pharmaceutical and life sciences industries. After graduation with honors from the Chemical Engineering Department of the Mendeleev Chemical Technology University where he specialized in Chemical technology of synthetic biologically active substances, he worked as a researcher, then senior researcher in the Immunomodulators laboratory at the Gerontology Research Institute of the Ministry of Health of the Russian Federation. In 1996 he was an intern at the US Marshall State University, Minnesota.
Dr. Kravchenko joined ChemRar Group of Companies in 1999 as a head of the Organic Synthesis Department at Contact Service LLC. Since March 2003 he has held the position of General Director of JSC Chemical Diversity Research Institute – a member of the ChemRar Group with over 200 employees engaged in research and development in the field of pharmacology. Dr. Kravchenko is an author and co-author of over 100 scientific publications and patents.

Nikolay Merkin, Ph. D.
General Director of ChemRar Ventures

Nikolay is an entrepreneur and angel investor with more than 15 years of experience in venture capital, focussing on investment opportunities in innovation or commercialization in the fields of biotechnology, pharmaceuticals, medical devices and in vitro diagnostics.

Nikolay has extensive experience in developing strategic, tactical and operational business plans, venture capital transactions and strategic financial management. Having held multiple management positions, he has a solid track record in transforming businesses. Currently supports ChemRar portfolio companies as well as identifies potential new ones.

Natalia Rabinovich
General Director of API-Tehnology - Development and manufacturing of active pharmaceutical ingredients
General Director of IPHARMA - Clinical trials & Drug approval CRO

Master’s degree in Finance at Stockholm University in 2005.

More than 12 years of corporate governance experience in the chemical and pharmaceutical industry. Monitoring of financial transactions and strategic partnership issues.

Irina Tyrnova
General Director of ChemRar Research Institute – R&D CRO

Irina Tyrnova joined ChemRar Group of Companies in 1998 and has since then successfully held several key roles in marketing and business development at ChemRar Group. She has extensive leadership experience in life science industry. Irina most recently was CEO at Viriom LLC, where she managed development efforts from preclinical study and clinical trials to product approval (market authorization) of the company’s first new generation drug for HIV therapy.

She has attended over 200 international presentations and meetings with business partners in France, Germany, Italy, Great Britain, Australia, Belgium, Spain, Finland etc, concluded more than 100 partnership agreements and more than 300 deals in Russia and around the world.